These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1137 related articles for article (PubMed ID: 29439259)

  • 1. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
    Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
    Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
    Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
    Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma.
    Li C; Wu M; Zong G; Wan C; Liu Q; Zhou H; Hua L; Chen Y; Chen X; Lu C
    Dig Dis Sci; 2017 Jan; 62(1):133-142. PubMed ID: 27921263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NKD1 correlates with a poor prognosis and inhibits cell proliferation by inducing p53 expression in hepatocellular carcinoma.
    Zhang S; Li J; Wang X
    Tumour Biol; 2016 Oct; 37(10):14059-14067. PubMed ID: 27507614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SIRT6 Overexpression Potentiates Apoptosis Evasion in Hepatocellular Carcinoma via BCL2-Associated X Protein-Dependent Apoptotic Pathway.
    Ran LK; Chen Y; Zhang ZZ; Tao NN; Ren JH; Zhou L; Tang H; Chen X; Chen K; Li WY; Huang AL; Chen J
    Clin Cancer Res; 2016 Jul; 22(13):3372-82. PubMed ID: 26861461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HBx-related long non-coding RNA DBH-AS1 promotes cell proliferation and survival by activating MAPK signaling in hepatocellular carcinoma.
    Huang JL; Ren TY; Cao SW; Zheng SH; Hu XM; Hu YW; Lin L; Chen J; Zheng L; Wang Q
    Oncotarget; 2015 Oct; 6(32):33791-804. PubMed ID: 26393879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudogene PDIA3P1 promotes cell proliferation, migration and invasion, and suppresses apoptosis in hepatocellular carcinoma by regulating the p53 pathway.
    Kong Y; Zhang L; Huang Y; He T; Zhang L; Zhao X; Zhou X; Zhou D; Yan Y; Zhou J; Xie H; Zhou L; Zheng S; Wang W
    Cancer Lett; 2017 Oct; 407():76-83. PubMed ID: 28823960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of a regulatory loop between DUSP1 and p53 contributes to hepatocellular carcinoma development and progression.
    Hao PP; Li H; Lee MJ; Wang YP; Kim JH; Yu GR; Lee SY; Leem SH; Jang KY; Kim DG
    J Hepatol; 2015 Jun; 62(6):1278-86. PubMed ID: 25617504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways.
    Chen SL; Liu LL; Wang CH; Lu SX; Yang X; He YF; Zhang CZ; Yun JP
    Mol Oncol; 2020 Feb; 14(2):373-386. PubMed ID: 31670863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FBI-1 promotes cell proliferation and enhances resistance to chemotherapy of hepatocellular carcinoma in vitro and in vivo.
    Fang F; Yang L; Tao Y; Qin W
    Cancer; 2012 Jan; 118(1):134-46. PubMed ID: 21713761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.
    Wang G; Chen JH; Qiang Y; Wang DZ; Chen Z
    World J Gastroenterol; 2015 Apr; 21(13):3983-93. PubMed ID: 25852285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcription factorIRX5 promotes hepatocellular carcinoma proliferation and inhibits apoptosis by regulating the p53 signalling pathway.
    Zhu L; Dai L; Yang N; Liu M; Ma S; Li C; Shen J; Lin T; Wang D; Pan W; Li X
    Cell Biochem Funct; 2020 Jul; 38(5):621-629. PubMed ID: 32153043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma progression by activating mTOR signaling pathway.
    Liu H; Wang X; Feng B; Tang L; Li W; Zheng X; Liu Y; Peng Y; Zheng G; He Q
    BMC Cancer; 2018 Jun; 18(1):661. PubMed ID: 29914442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulated TRIM11 Exerts its Oncogenic Effects in Hepatocellular Carcinoma Through Inhibition of P53.
    Liu J; Rao J; Lou X; Zhai J; Ni Z; Wang X
    Cell Physiol Biochem; 2017; 44(1):255-266. PubMed ID: 29190611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma.
    Wang F; Feng Y; Li P; Wang K; Feng L; Liu YF; Huang H; Guo YB; Mao QS; Xue WJ
    Oncotarget; 2016 Jan; 7(4):4279-97. PubMed ID: 26701853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ku80 functions as a tumor suppressor in hepatocellular carcinoma by inducing S-phase arrest through a p53-dependent pathway.
    Wei S; Xiong M; Zhan DQ; Liang BY; Wang YY; Gutmann DH; Huang ZY; Chen XP
    Carcinogenesis; 2012 Mar; 33(3):538-47. PubMed ID: 22226916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell proliferation, apoptosis and the related regulators p27, p53 expression in hepatocellular carcinoma.
    Jing Z; Nan KJ; Hu ML
    World J Gastroenterol; 2005 Apr; 11(13):1910-6. PubMed ID: 15800979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway.
    Zhao J; Wozniak A; Adams A; Cox J; Vittal A; Voss J; Bridges B; Weinman SA; Li Z
    J Exp Clin Cancer Res; 2019 Jun; 38(1):252. PubMed ID: 31196136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21.
    Zhang L; Chen J; Ning D; Liu Q; Wang C; Zhang Z; Chu L; Yu C; Liang HF; Zhang B; Chen X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):101. PubMed ID: 30808376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of Nedd4L predicts poor prognosis, promotes tumor growth and inhibits MAPK/ERK signal pathway in hepatocellular carcinoma.
    Zhao F; Gong X; Liu A; Lv X; Hu B; Zhang H
    Biochem Biophys Res Commun; 2018 Jan; 495(1):1136-1143. PubMed ID: 29175326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.